INDEGENE
Back to Balance Sheet
|
INDEGENE Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹56 Cr | ₹435 Cr | ₹584 Cr | ₹80 Cr | ₹27 Cr |
What is the latest Total Non-Current Liabilities ratio of INDEGENE ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹56 Cr |
| Mar2024 | ₹435 Cr |
| Mar2023 | ₹584 Cr |
| Mar2022 | ₹80 Cr |
| Mar2021 | ₹27 Cr |
How is Total Non-Current Liabilities of INDEGENE Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹56 Cr | -87.12 | |
| Mar2024 | ₹435 Cr | -25.54 | |
| Mar2023 | ₹584 Cr | 630.10 | |
| Mar2022 | ₹80 Cr | 198.58 | |
| Mar2021 | ₹27 Cr | - | |
Compare Total Non-Current Liabilities of peers of INDEGENE
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDEGENE | ₹11,973.3 Cr | 5.2% | 4.3% | -19.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹412,062.0 Cr | 0.4% | 2.6% | NA | Stock Analytics | |
| DIVIS LABORATORIES | ₹164,192.0 Cr | -4.5% | 0.7% | 3.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹144,129.0 Cr | 5% | 4.1% | 37.2% | Stock Analytics | |
| CIPLA | ₹108,513.0 Cr | -0.5% | -3.4% | -6.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,250.0 Cr | 1.2% | 10.2% | 4.8% | Stock Analytics | |
INDEGENE Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDEGENE | 5.2% |
4.3% |
-19.8% |
| SENSEX | -1% |
-0.1% |
7.9% |
You may also like the below Video Courses